Personalized telemedicine in human proportions
A body, a medical history, a future. Semaglutide research gets more interesting when all of them enter the picture.
Semaglutide research
A weight-loss percentage can describe a substantial achievement while leaving much of a life undescribed. In the STEP 1 trial, adults with overweight or obesity without diabetes had a mean body-weight change of −14.9% with semaglutide versus −2.4% with placebo at 68 weeks. The size of that finding earns my admiration. The word personalized asks for something more intimate: how does a result fit the person who has to live with it?
The fitting problem is my main concern. Appetite has a biology; a medical history changes the stakes; a future extends beyond the first celebrated result. Weight can take its place among those concerns without swallowing the entire conversation. The name Personalized Telemedicine is an editorial question here: how much of a person survives the summary?
Appetite biology
In rodent experiments, semaglutide reduced food intake and altered food preference without decreasing energy expenditure. The investigators traced distributed pathways through the brain. These were mice and rats, so their findings need their animal setting attached.
The appetite essay begins with that piece of biology. Appetite’s active organization is the attraction here, with several places in the brain involved. The question becomes more interesting than whether a person can summon enough determination. How far the animal account carries into a particular human life remains a different question.
Cardiovascular disease
SELECT studied adults with established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the trial's combined cardiovascular outcome versus placebo. The medical history in that sentence gives the result its particular importance.
In my judgement, this is where the conversation becomes especially consequential. A weight target and a cardiovascular event carry different meanings, and the same treatment can have findings worth discussing under each. The cardiovascular essay follows the events, the symptoms and an eye-related safety signal that prevent a simple success story from feeling complete.
Treatment duration
STEP 5 reported sustained weight reduction over 104 weeks with semaglutide, significantly greater than placebo in adults with overweight or obesity. That longer on-treatment observation moves the question from reaching a target toward the time spent living with a change.
The essay on longer treatment sets it beside the earlier STEP 1 result. My allegiance is to the future person as much as the person at the moment of greatest change. A version of personalization that runs out of interest at the target weight leaves my central objection unanswered.